Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
February 26, 2016 7:00 AM ESTSAN DIEGO, Feb. 26, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the fourth quarter and year ended December 31, 2015.
"Since the introduction of Contrave® to the United States market in October 2014, Takeda field representatives have engaged approximately 100,000 health care providers in nearly 1.1 million product discussions. 55,000 practitioners have written more than 765,000 prescriptions of Contrave. Levels of aided and unaided awareness are now high among HCPs," said Michael Narachi, CEO of Orexigen. "With this strong early effort, Contrave has quickly been established as the most... More
